

# CONTENTS

---

• List of Tables	i
• List of Figures	ii-iv
• Preface	v-vi
<b>Chapter 1: INTRODUCTION</b>	<b>1-7</b>
<b>Chapter 2: LITERATURE REVIEW</b>	<b>8-39</b>
2.1 Cancer	8
2.1.1 <i>Global Burden in cancer</i>	10
2.1.2 <i>Cell Signaling Pathways and Cancer</i>	11
2.2 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1)	15
2.2.1 <i>Targeting PDK1 In Cancer</i>	18
2.3 Flavonoids	20
2.4 Minimization	21
2.5 Molecular Docking	22
2.5.1 <i>C-DOCKER</i>	23
2.5.1.1 <i>CDOCKER Protocol</i>	24
2.5.2 <i>LIGAND FIT</i>	25
2.5.2.1 <i>Site search</i>	25
2.5.2.2 <i>Conformational search</i>	26
2.5.2.3 <i>Ligand fitting</i>	26

2.6 Pharmacophore	27
2.6.1 <i>List of features available for pharmacophore generation</i>	28
2.6.1.1 <i>HB ACCEPTOR (vector)</i>	28
2.6.1.2 <i>HB ACCEPTOR lipid (vector)</i>	28
2.6.1.3 <i>HB DONOR (vector)</i>	28
2.6.1.4 <i>HYDROPHOBIC (scalar)</i>	28
2.6.1.5 <i>HYDROPHOBIC ALIPHATIC (scalar)</i>	29
2.6.1.6 <i>HYDROPHOBIC AROMATIC (scalar)</i>	29
2.6.1.7 <i>NEG CHARGE (atom)</i>	29
2.6.1.8 <i>NEG IONIZABLE (point)</i>	29
2.6.1.9 <i>POS CHARGE (atom)</i>	29
2.6.1.10 <i>POS IONIZABLE (point)</i>	30
2.6.1.11 <i>RING AROMATIC (vector and plane)</i>	30
2.6.1.12 <i>Principal</i>	30
2.6.1.13 <i>MaxOmitFeat</i>	30
2.6.2 <i>Hypogen</i>	31
2.6.2.1 <i>Hypogen training set conditions</i>	32
2.6.2.2 <i>Hypothesis considerations</i>	32
2.7 Molecular Dynamic Simulation	32
2.7.1 <i>Performance analysis</i>	34
2.7.2 <i>Analysis of result</i>	34

2.8 ADME Analysis	36
2.8.1 <i>Lipinski rule of five</i>	36
2.8.2 <i>LogP (octanol/water partition coefficient)</i>	36
2.8.3 <i>Octanol-water partition coefficient logP</i>	37
2.8.4 <i>Molecular Polar Surface Area TPSA</i>	37
2.8.5 <i>ADMET-Absorption</i>	38
2.8.6 <i>Protein Binding module</i>	39
2.8.7 <i>Volume of Distribution module</i>	39
<b>Chapter 3: 3D QSAR BASED DESIGNING OF</b>	<b>40-67</b>
<b>    PHARMACOPHORE AND PHARMACOPHORE</b>	
<b>    BASED VIRTUAL SCREENING</b>	
3.1 Introduction	40
3.2 Material and methods	42
3.2.1 <i>General methodology</i>	42
3.2.1.1 <i>Hypogen</i>	42
3.2.1.2 <i>Fisher Randomization Test</i>	42
3.2.1.3 <i>Lipinski Filtration</i>	42
3.2.1.4 <i>Ligandfit</i>	42
3.2.2 <i>Data set for Pharmacophore Analysis</i>	43
3.2.3 <i>Pharmacophore Modelling</i>	44
3.2.4 <i>Model Validation</i>	46
3.2.5 <i>Decoy Set Validation</i>	47
3.2.6 <i>Virtual Screening and ADMET Analysis</i>	48

3.3 Results and Discussion	49
3.3.1 <i>Pharmacophore Modelling</i>	49
3.3.2 <i>Cost analysis</i>	55
3.3.3 <i>Validation of Pharmacophore model</i>	56
3.3.3.1 <i>Test Set Validation</i>	56
3.3.3.2 <i>Fisher validation</i>	61
3.3.4 <i>Pharmacophore based virtual screening</i>	63
3.3.5 <i>Molecular Docking studies</i>	63
i) Compound_1 docking Detail	64
ii) Other Compounds docking Details	64
<b>Chapter 4: DOCKING BASED SCREENING AND VALIDATIONS OF SOME SELECTED NATURAL INHIBITORS AGAINST PDK1 KINASE</b>	<b>68-85</b>
4.1 Introduction	68
4.2 Material and Methods	69
4.2.1 <i>Compounds used for study</i>	69
4.2.2 <i>Molecular docking</i>	74
4.2.3 <i>Protein preparation</i>	75
4.2.4 <i>2 D Plot of protein ligand interactions</i>	77
4.2.5 <i>Molecular dynamic simulation study of     Myricetin in water</i>	77
4.3 Results and Discussions	78
4.3.1 <i>Molecular Docking Details</i>	78
4.3.2 <i>Molecular Dynamic Simulation details</i>	82

**Chapter 5: MOLECULAR DOCKING AND *INSILICO* 86-105**

**ADME STUDY OF MYRICETIN AND THEIR  
ANALOGUES**

5.1 Introduction	86
5.2 Material and Methods	87
5.2.1 <i>Chemical similarity search</i>	87
5.2.2 <i>Preparation of ligands</i>	87
5.2.3 <i>Lipinski Filter</i>	88
5.2.5 <i>Molecular docking simulation</i>	89
5.2.6 <i>ADME Study</i>	90
5.2.7 <i>Toxicity Prediction</i>	91
5.3 Results and Discussions	
5.3.1 <i>Drug Likeness Study</i>	92
5.3.2 <i>ADME Study</i>	93
5.3.3 <i>Toxicity Prediction</i>	98
5.3.4 <i>Molecular Docking Results</i>	1000

**Chapter 6: CONCLUSIONS AND FUTURE DIRECTIONS 106-110**

**REFERENCES 111-127**

- **LIST OF PUBLICATIONS AND PRESENTATIONS**
- **PERSONAL PROFILE**

